HIV (Human Immunodeficiency Virus) is a chronic but fully manageable condition. With modern antiretroviral therapy, people living with HIV achieve an undetectable viral load, protect their long-term immune health, and live a near-normal life expectancy. The pages collected here cover every aspect of HIV care that matters to patients — from understanding your treatment options to navigating the cost of your medication.
Every guide on Kolana Health is written in plain language, medically reviewed before publication, and updated when evidence changes. There are no ads, no sponsored content, and no financial relationship with any pharmaceutical company or pharmacy.
What Is HIV
HIV is a virus that attacks CD4 cells (T cells) — the immune system’s primary defense against infection. Without treatment, HIV progressively damages the immune system until it can no longer defend the body against infections and cancers that a healthy immune system would control. That advanced stage is called AIDS.
With treatment, this progression is prevented entirely for the vast majority of people. HIV is transmitted through specific bodily fluids: blood, semen, vaginal fluids, rectal fluids, and breast milk. It is not transmitted through casual contact, saliva, air, water, food, or insects.
HIV is not a death sentence. With consistent antiretroviral treatment, people living with HIV today have a near-normal life expectancy and cannot transmit the virus to others when their viral load is undetectable.
- Cause: Human Immunodeficiency Virus (HIV-1 is the predominant global strain)
- Transmission: Blood, sexual fluids, breast milk — not casual contact
- Diagnosis: HIV antibody/antigen test; confirmed by viral load and CD4 count
- Treatment: Antiretroviral therapy (ART) — highly effective, typically once-daily
- Goal of treatment: Undetectable viral load (<50 copies per mL of blood)
- U=U: Undetectable = Untransmittable — confirmed by PARTNER and HPTN 052 studies
- Life expectancy: Near-normal with consistent, sustained treatment
- Cure: Not yet widely available; active research is ongoing
Antiretroviral Therapy (ART)
Antiretroviral therapy is the combination of medications that suppresses HIV replication in the body. ART does not eliminate HIV, but reduces the viral load to undetectable levels — protecting the immune system, preventing progression to AIDS, and preventing transmission to others through sex.
Current DHHS guidelines recommend starting ART as soon as possible after diagnosis, regardless of CD4 count or viral load. Most modern regimens are a single tablet taken once daily. Adherence is critical: missed doses allow the virus to replicate and can lead to drug resistance that limits future treatment options.
U=U — Undetectable equals Untransmittable: A person living with HIV who maintains an undetectable viral load on ART cannot sexually transmit HIV to a partner. This is confirmed by the landmark PARTNER study (2016, 2019) and HPTN 052, and endorsed by the CDC, WHO, NIH, and every major HIV medical association. Source: CDC.
The main classes of antiretroviral drugs used today are integrase strand transfer inhibitors (INSTIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and capsid inhibitors. Most patients today are prescribed an INSTI-based regimen for its high efficacy, high barrier to resistance, and favorable side effect profile.
HIV Medications — Full Guide Index
The guides below cover every major HIV medication in depth: how it works, what it costs, what the side effects are, how to access financial assistance, and how it compares to alternatives. This index grows as new guides are published.
Complete Regimens — Single Tablet, Once Daily
PrEP Medications — HIV Prevention
All HIV Topics on Kolana Health
- Biktarvy cost 2026
- Biktarvy without insurance
- Biktarvy generic
- Biktarvy side effects
- Dovato cost 2026
- Dovato side effects
- Biktarvy vs Dovato
- Cabenuva cost 2026
- Symtuza cost 2026
- PrEP — complete guide
- PEP — complete guide
- Descovy PrEP cost
- Apretude cost
- CD4 count explained
- Viral load explained
- U=U — what it means for you
- HIV treatment guide 2026
- Newly diagnosed — what to do first
What HIV Medications Cost in 2026
HIV medications carry some of the highest list prices in U.S. pharmacy. Biktarvy’s wholesale cost is $4,216 per month as of January 2026. But list price is not what most patients pay. The United States has a layered system of manufacturer assistance programs, federal safety nets, and independent nonprofit foundations designed specifically to ensure that cost is never an absolute barrier to HIV treatment.
- Commercial insurance + copay card: $0–$5
- Medicare Part D + Extra Help (LIS): $4–$9
- Medicaid: $0–$3 in most states
- Uninsured + Gilead PAP or state ADAP: $0
- Uninsured with no assistance programs: $3,800–$5,300+ (retail cash price)
If you are facing a cost barrier: do not stop your medication. Interrupting antiretroviral therapy causes viral rebound, immune decline, and resistance that can limit your future treatment options. Contact your prescriber, insurer, and Gilead Advancing Access (1-800-226-2056) before making any decision about stopping or skipping doses. Programs exist for every coverage situation.
See the full cost breakdown for each medication in the guides linked above. The most detailed guide covers the most prescribed HIV treatment: Biktarvy cost in 2026 →
Financial Assistance Programs for HIV Medications
Every uninsured or underinsured person living with HIV in the United States qualifies for at least one of the following programs. Together they cover every coverage situation:
- Gilead Advancing Access — Copay card for commercially insured patients (up to $7,200/year); free medication through the Patient Assistance Program (PAP) for uninsured patients. Call 1-800-226-2056 or enroll online.
- AIDS Drug Assistance Program (ADAP) — State-run programs providing HIV medications at no cost or minimal copay to eligible low-income individuals. Find your state’s program at nastad.org/adap-watch.
- Ryan White HIV/AIDS Program — The largest federal safety-net program for people with HIV who are uninsured or underinsured. Funds clinics, medications through ADAP, and support services. Find a clinic at findhivcare.hrsa.gov.
- Patient Advocate Foundation — Copay relief and free case management for insurance denials and appeals.
- PAN Foundation — Grants covering copays, deductibles, and insurance premiums for HIV treatment. Critical for Medicare patients who cannot use manufacturer copay cards.
- HealthWell Foundation — HIV/AIDS fund when funding is available.
- 340B Drug Pricing Program — If you receive care at a Ryan White clinic or federally qualified health center, your medications may be available at significantly reduced cost through 340B pricing. Ask your clinic directly if they participate.
Medicare patients: Gilead’s copay card cannot be used with Medicare, Medicaid, or other government-funded insurance. The PAN Foundation, HealthWell Foundation, and Patient Advocate Foundation all operate programs specifically designed for Medicare patients with HIV. These nonprofits are your primary resource if you are on Medicare and facing high medication costs.
Prevention — PrEP and PEP
HIV is highly preventable with two medication-based strategies that provide near-complete protection for HIV-negative individuals at risk of exposure.
PrEP (Pre-Exposure Prophylaxis) is medication taken by HIV-negative individuals before potential exposure to HIV. When taken consistently, PrEP reduces the risk of HIV from sex by approximately 99% and from injection drug use by at least 74%. Current FDA-approved options include Truvada (oral, generic available), Descovy (oral), and Apretude (injectable, every 2 months). PrEP is covered by most insurance plans and available at no cost to uninsured individuals through the federal Ready, Set, PrEP program.
PEP (Post-Exposure Prophylaxis) is emergency medication taken after a potential HIV exposure. PEP must be started within 72 hours of exposure and taken for 28 consecutive days. It is not a substitute for PrEP but can prevent HIV infection when initiated quickly after a high-risk exposure event.
- PrEP — complete patient guide
- PEP — complete patient guide
- Descovy PrEP cost
- Apretude injectable PrEP cost
Living With HIV
A diagnosis of HIV changes your life, but it does not end it. With consistent treatment, people living with HIV today maintain near-normal life expectancy, cannot transmit the virus to sexual partners, and live full and active lives. The guides below address the practical questions that come after diagnosis — monitoring, mental health, relationships, and day-to-day life with the condition.
- Newly diagnosed — what to do first
- CD4 count — what it means
- Viral load — what it means
- U=U — what it means for you
- HIV treatment guide 2026
Frequently Asked Questions
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is the most widely prescribed HIV-1 treatment in the United States as of 2026. It is a complete single-tablet regimen taken once daily. Other commonly prescribed options include Dovato, Cabenuva (injectable, monthly or every two months), and Descovy-based regimens.
Yes. With consistent antiretroviral therapy, most people living with HIV achieve an undetectable viral load within 3–6 months of starting treatment. U=U — Undetectable equals Untransmittable — means a person with an undetectable viral load cannot sexually transmit HIV to a partner. This is confirmed by the PARTNER and HPTN 052 studies and endorsed by the CDC, WHO, and NIH.
HIV medications carry high list prices — Biktarvy’s wholesale cost is $4,216 per month in 2026 — but most insured patients pay $0 to $5 per month with manufacturer copay card assistance. Uninsured patients may qualify for free medication through Gilead’s Patient Assistance Program or their state ADAP. See the full Biktarvy cost guide for a detailed breakdown by coverage type.
HIV is the virus. AIDS is the most advanced stage of HIV infection, defined by a CD4 count below 200 cells per cubic millimeter or the presence of certain opportunistic infections. With modern ART started promptly after diagnosis, the vast majority of people living with HIV never develop AIDS.
PrEP (pre-exposure prophylaxis) is medication taken by HIV-negative individuals to prevent infection. When taken as prescribed, PrEP reduces the risk of HIV from sex by approximately 99%. Current options include Truvada, Descovy, and Apretude (injectable, every 2 months). PrEP is recommended for anyone at substantial risk of HIV exposure. See the complete PrEP guide →
Programs cover every situation: Gilead’s copay card (commercially insured, up to $7,200/year), Gilead’s Patient Assistance Program (uninsured), state ADAP programs, Ryan White clinics, and nonprofit foundations including the Patient Advocate Foundation, PAN Foundation, and HealthWell Foundation. Call Gilead Advancing Access at 1-800-226-2056 as a first step regardless of your insurance status.
There is currently no widely available cure for HIV. A small number of patients have achieved functional cures through stem cell transplants under very specific clinical conditions. Research into curative approaches — including broadly neutralizing antibodies and gene editing — is active and ongoing. For the vast majority of people living with HIV, daily ART enables near-normal life expectancy and full quality of life.
Start treatment as soon as possible — current guidelines recommend beginning ART immediately after diagnosis. Find a local Ryan White clinic at findhivcare.hrsa.gov, locate your state ADAP at nastad.org/adap-watch, and call Gilead Advancing Access at 1-800-226-2056 to understand your medication assistance options. Modern HIV treatment is highly effective, well-tolerated, and typically available at low or no cost.
How we reviewed this article:
Kolana Health follows strict sourcing guidelines and relies on peer-reviewed studies, government agencies (CDC, NIH, HRSA, FDA), and established medical associations (DHHS, IDSA, IAS-USA). All content is reviewed by a licensed clinician before publication and updated when evidence changes. Learn more in our editorial policy.
Read our editorial policy →Sources & References
- CDC — HIV Basics: cdc.gov/hiv/basics
- CDC — U=U: cdc.gov
- NIH DHHS — Guidelines for ART in Adults and Adolescents: clinicalinfo.hiv.gov
- PARTNER Study — Rodger AJ et al. (2019). JAMA: jamanetwork.com
- HPTN 052 — Cohen MS et al. (2016). NEJM: nejm.org
- Ryan White HIV/AIDS Program: ryanwhite.hrsa.gov
- HRSA — Find HIV Care: findhivcare.hrsa.gov
- NASTAD — ADAP Watch: nastad.org/adap-watch
- Gilead Advancing Access: gileadadvancingaccess.com
- Gilead Price Info — Biktarvy WAC 2026: gileadpriceinfo.com
- CDC — PrEP: cdc.gov/hiv/risk/prep
- FDA — Biktarvy Prescribing Information (2025): accessdata.fda.gov